Clinical trial phases describe the main questions a study is designed to answer. The phase is not a rating of whether a study is good or bad, and it does not predict whether an individual participant will benefit. Instead, phases help researchers organize the step-by-step evaluation of an investigational drug, biologic, device, or treatment approach.
Before clinical trials begin
Before a new drug is studied in people, researchers conduct laboratory and preclinical work to learn about its biological activity, formulation, and potential safety concerns. A sponsor generally submits information to the U.S. Food and Drug Administration before beginning regulated clinical research. Every clinical trial follows a written protocol that explains the objectives, eligibility criteria, treatments or procedures, visit schedule, safety monitoring, and plan for analyzing results.
Phase 1: safety and dose
Phase 1 studies are usually small and closely monitored. Their main goals may include learning how the intervention behaves in the body, identifying common side effects, determining a dose or dose range, and finding a practical schedule or method of administration. In many cancer trials, participants have the disease being studied. Although researchers may observe early signs of activity, proving effectiveness is generally not the primary purpose of Phase 1.
Phase 2: preliminary evidence of activity
Phase 2 studies usually include more participants with the condition of interest. Researchers continue monitoring safety while examining whether the treatment shows the intended biological or clinical effect—for example, whether a tumor shrinks, disease growth slows, symptoms improve, or another prespecified outcome changes. A Phase 2 result may help determine whether a larger comparative study is justified.
Phase 3: comparison and confirmation
Phase 3 studies often enroll hundreds or thousands of participants. They commonly compare an investigational approach with a current standard treatment, placebo when ethically appropriate, or another control. Random assignment may be used to reduce bias. Researchers examine benefits, risks, and less common side effects in a larger population. Results may support a request for regulatory approval, but approval is never guaranteed.
Phase 4: research after approval
Phase 4 studies occur after a product has been approved for a particular use. They may evaluate longer-term safety, effectiveness in broader populations, rare side effects, quality of life, additional uses, or how the treatment performs in routine care. Regulatory agencies also use post-market safety systems outside formal Phase 4 trials.
Phase 0 and combined-phase studies
Some early exploratory studies are called Phase 0. They may give a very small dose to a limited number of participants to study how an agent behaves in the body; they are not intended to provide treatment benefit. Some protocols combine phases, such as Phase 1/2 or Phase 2/3. A combined label means that one protocol addresses questions associated with more than one phase, often with planned transitions or separate study portions.
What the phase does not tell you
The phase alone does not describe all risks, the quality of the study, whether the intervention is appropriate for you, or whether it will work. Two trials in the same phase can have very different designs, procedures, and eligibility requirements. Review the protocol-specific information and discuss standard treatment alternatives with your healthcare professional.
Questions to ask
- What question is this study designed to answer?
- Why is this phase appropriate for the intervention?
- What is known from earlier laboratory or clinical studies?
- How are treatment groups assigned, and could I receive a placebo?
- Which visits, tests, biopsies, or hospital stays are required?
- What are the known and possible risks, benefits, and alternatives?
- What happens if the study treatment is not helping or causes side effects?
Reliable sources
This article is general educational information, not medical advice or a statement that a specific trial is available. Trial design and phase definitions can vary by product and protocol. Discuss your options with your healthcare professional and the study team.